Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study - PubMed (original) (raw)
. 1988 Aug 1;48(15):4399-404.
Affiliations
- PMID: 3390835
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study
G A Kune et al. Cancer Res. 1988.
Abstract
The associations between colorectal cancer risk and several chronic illnesses, operations, and various medications were examined in 715 colorectal cancer cases and 727 age/sex-matched controls in data derived from a large, comprehensive, population-based study of this cancer conducted in Melbourne, Australia. There was a statistically significant deficit among cases of hypertension, heart disease, stroke, chronic chest disease, and chronic arthritis and a statistically significant excess of "hemorrhoids" among cases, and all of these differences were consistent for both colon and rectal cancer and for both males and females. Although no statistically significant differences were found for other cancers, there were twice as many breast cancers among cases (16) than among controls and also there were 9 uterine cancers among cases and only 2 among controls. There was a statistically significant deficit among cases in the use of aspirin-containing medication and vitamin supplements, and this was consistent for both colon and rectal cancer and for both males and females. There was a statistically significant excess of large bowel polypectomy among cases. The modeling of these significant associations simultaneously in a logistic regression equation indicated that hypertension, heart disease, chronic arthritis, and aspirin use were each independent effects and consistent for both colon and rectal cancer for both males and females and also that these effects were independent of dietary risk factors previously described in the Melbourne study. The possible relevance of these findings towards an understanding of colorectal cancer risk and etiology is discussed.
Similar articles
- Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988.
Kune GA, Kune S, Watson LF. Kune GA, et al. Int J Epidemiol. 2007 Oct;36(5):951-7. doi: 10.1093/ije/dym193. Epub 2007 Oct 5. Int J Epidemiol. 2007. PMID: 17921195 - Body weight and physical activity as predictors of colorectal cancer risk.
Kune GA, Kune S, Watson LF. Kune GA, et al. Nutr Cancer. 1990;13(1-2):9-17. doi: 10.1080/01635589009514041. Nutr Cancer. 1990. PMID: 2300499 - Relation of family history of cancer and environmental factors to the risk of colorectal cancer: a case-control study.
Kotake K, Koyama Y, Nasu J, Fukutomi T, Yamaguchi N. Kotake K, et al. Jpn J Clin Oncol. 1995 Oct;25(5):195-202. Jpn J Clin Oncol. 1995. PMID: 7474407 - Serum cholesterol level and the risk of colorectal cancer.
Törnberg S. Törnberg S. Biomed Pharmacother. 1988;42(6):381-5. Biomed Pharmacother. 1988. PMID: 3064822 Review. - Etiology of colorectal cancer with emphasis on mechanism of action and prevention.
Weisburger JH, Wynder EL. Weisburger JH, et al. Important Adv Oncol. 1987:197-220. Important Adv Oncol. 1987. PMID: 3331381 Review. No abstract available.
Cited by
- Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study.
Ahmadi A, Mobasheri M, Hashemi-Nazari SS, Baradaran A, Choobini ZM. Ahmadi A, et al. J Res Med Sci. 2014 Sep;19(9):850-4. J Res Med Sci. 2014. PMID: 25535499 Free PMC article. - Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid.
Chattopadhyay M, Kodela R, Duvalsaint PL, Kashfi K. Chattopadhyay M, et al. Pharmacol Res Perspect. 2016 Mar 4;4(2):e00224. doi: 10.1002/prp2.224. eCollection 2016 Apr. Pharmacol Res Perspect. 2016. PMID: 27069635 Free PMC article. - Chemoprevention in Lynch syndrome.
Burn J, Mathers JC, Bishop DT. Burn J, et al. Fam Cancer. 2013 Dec;12(4):707-18. doi: 10.1007/s10689-013-9650-y. Fam Cancer. 2013. PMID: 23880960 Clinical Trial. - How prevalent is cancer family syndrome?
Kee F, Collins BJ. Kee F, et al. Gut. 1991 May;32(5):509-12. doi: 10.1136/gut.32.5.509. Gut. 1991. PMID: 2040473 Free PMC article. - Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.
Crawford S. Crawford S. Front Pharmacol. 2013 Jun 25;4:68. doi: 10.3389/fphar.2013.00068. eCollection 2013. Front Pharmacol. 2013. PMID: 23805101 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources